أخبار

European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia

European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia

Bristol Myers Squibb (BMS) & Acceleron Pharma announced today that the European Commission approved Reblozyl (luspatercept) for the treatment of Transfusion-Dependent β-#Thalassaemia (TDT) in adult patients. Reblozyl has the potential to…
Gene Therapy & Thalassaemia: A TIF Survey

Gene Therapy & Thalassaemia: A TIF Survey

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies …
25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia

25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia

TIF was excited to participate in the 25th European Hematology Association (EHA) Annual  Virtual Congress, held this year virtually on 11 – 21 June 2020. Dr Androulla Eleftheriou (TIF Executive…
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America

COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America

On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a fruitful discussion with patient advocates from the AMRO region about…
COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients

COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients

An Expert Panel of Six Medical Professionals from various countries, such as India, the UK, Italy and Saudi Arabia, shared their experiences with TIF on the impact of the COVID-19…
eThalED Webinar Series: Access to New Therapies – Reblozyl

eThalED Webinar Series: Access to New Therapies – Reblozyl

The 1st webinar for Medical Specialists organised in the context of TIF’s eThalEd online course is here. Dr Antonio Piga, Professor of Paediatrics & Dean of the Medicine School at…
TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients

TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients

See what patients from various countries across the world who successfully took TIF‘s Thal e-Course, the ultimate self-paced, interactive, online Εducational Course for individuals with thalassaemia and their families, have to say…
TIF and Hemanext® Inc. Announce New Strategic Alliance

TIF and Hemanext® Inc. Announce New Strategic Alliance

TIF, a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other haemoglobin disorders across the world, and Hemanext Inc., a privately held medical…
TIF Launches Online Petition to Promote ”Equitable Access to Safe and Adequate Blood”

TIF Launches Online Petition to Promote ”Equitable Access to Safe and Adequate Blood”

A few days before the celebration of the World Blood Donor Day 2020, TIF has launched an online petition, co-signed by the European Blood Alliance (EBA), to promote ”Equitable Access…
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia

FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…
زر الذهاب إلى الأعلى
إغلاق
إغلاق